Meet Jeffrey Lu, the CEO of Engine Biosciences who shares how Crispr technology and a network approach to drug discovery is accelerating the discovery of solutions to disease. Michelle Martin finds out more about the venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine and its progress in the field of liver cancer.  This interview is part of a special series featuring speakers  in collaboration with the Peak Magazine's Next Gen Leader Series